HEMATOLOGY

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

“We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future."

David Sallman, MD, discussed the challenges and new studies of high-risk myelodysplastic syndrome therapies.

Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.

During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

The REMARK trial aims to assess the safety and efficacy of RVU120 in patients with lower-risk myelodysplastic syndromes.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination with azacitidine and venetoclax in AML.

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.

Sonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.

Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.

Stefan Barta, MD, discusses the heterogeneity of T-cell lymphoma, highlighting that a one-size-fits-all approach is ineffective and emphasizing the need for tailored treatment approaches.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

Jamie Koprivnikar, MD, provides key takeaways for optimizing anemia management in patients with lower-risk MDS, highlighting unmet needs in treating anemia and improving patient outcomes.

An expert on the treatment of patients with myelodysplastic syndromes provides clinical insights on dosing practices and considerations for luspatercept.

Jamie Koprivnikar, MD, discusses factors that signal a need to transition a patient with lower-risk MDS from an ESA to another therapy.

Highlighting recent data from a post hoc analysis from the COMMANDS trial, a hematologist-oncologist offers insights on important factors to consider when assessing quality of life in patients with MDS.

Jamie Koprivnikar, MD, discusses how findings from the COMMANDS trial can be used to inform treatment decisions for patients based on serum EPO levels and the presence or absence of ring sideroblasts.

Focusing on molecular prognostic models in LR-MDS, Jamie Koprivnikar, MD, shares insights gleaned from the COMMANDS trial on how mutational burden impacts response.

A hematologist-oncologist provides expert perspectives on the development and implementation of the IPSS-M as a clinical-molecular prognostic model in lower-risk MDS.